Alnylam Pharmaceuticals has made significant headlines with its bold move of investing
$250M to equip their flagship facility with cutting-edge siRNA production tech, indicating a strong commitment to RNAi therapeutics. This move, targeted to meet growing global demand, could potentially prove game changer for Alnylam. Similarly, with its manufacturing expansion and extra-hepatic RNAi delivery, Alnylam’s $250M Norton facility upgrade aims to consolidate the need for 20 plants down to just 2. In addition to its ambitious investment, Alnylam also announced the Health Canada Approval of
AMVUTTRA® (vutrisiran), the first and only RNAi Therapeutic for cardiomyopathy in Adult Patients. Furthermore, there have been several modifications to Alnylam's board, raising questions regarding management incentives and risk profile. Despite the 67.8% surge in 2025, analysts have conflicting views on Alnylam's valuation and stock performance, with some investors questioning if it's too late to consider Alnylam. Highlighting financial performance, Alnylam reported $492M AMVUTTRA sales, and subsequently raised its 2025 revenue guidance.
Alnylam Pharmaceuticals News Analytics from Thu, 31 Jul 2025 07:00:00 GMT to Sun, 21 Dec 2025 00:17:39 GMT -
Rating 8
- Innovation 6
- Information 9
- Rumor -4
